(Q30597618)

17 November 2017

Best practice in the use of natalizumab in multiple sclerosis (English)

1 reference

17 November 2017

0 references

1 reference

Oscar Fernández

1

1 reference

17 November 2017

1 March 2013

1 reference

Therapeutic advances in neurological disorders

17 November 2017

1 reference

17 November 2017

6

1 reference

17 November 2017

2

1 reference

17 November 2017

69-79

1 reference

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

17 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Spanish consensus on the use of natalizumab (Tysabri(®))--2011.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Natalizumab in pediatric multiple sclerosis patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Three years of experience: the Italian registry and safety data update.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

20 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Identification of HIV-associated progressive multifocal leukoencephalopathy: magnetic resonance imaging and spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Progressive multifocal leukoencephalopathy in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285612470401

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582310

Progressive multifocal leukoencephalopathy

26 November 2018

1 reference

12 December 2020

Natalizumab use in pediatric multiple sclerosis

1 reference

12 December 2020

'Natalizumab in paediatric multiple sclerosis and service implication'

1 reference

12 December 2020

Natalizumab dosage suspension: are we helping or hurting?

1 reference

12 December 2020

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

12 December 2020

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285612470401

1 reference

17 November 2017

1 reference

PMC publication ID

3582310

17 November 2017

PubMed publication ID

23483450

1 reference

PMC publication ID

3582310